Seminars in Oncology
Volume 30, Issue 6 , Pages 817-825 , December 2003

Follow-up care of breast cancer survivors

  • Ann H Partridge

      Affiliations

    • Dana-Farber Cancer Institute, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
    • Corresponding Author InformationAddress reprint requests to Ann H. Partridge, MD, MPH, Breast Oncology Center, Dana-Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    • ,
  • Eric P Winer

      Affiliations

    • Dana-Farber Cancer Institute, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
    • ,
  • Harold J Burstein

      Affiliations

    • Dana-Farber Cancer Institute, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

References 

  1. Jemal A, Murray T, Samuels A, et al.  Cancer statistics, 2003. CA Cancer J Clin. 2003;53:5–26
  2. Winchester DP, Jeske JM, Goldschmidt RA. The diagnosis and management of ductal carcinoma in-situ of the breast. CA Cancer J Clin. 2000;50:184–200
  3. Burstein HJ, Winer EP. Primary care for survivors of breast cancer. N Engl J Med. 2000;343:1086–1094
  4. Hewitt M, Breen N, Devesa S. Cancer prevalence and survivorship issues (Analyses of the 1992 National Health Interview Survey). J Natl Cancer Inst. 1999;91:1480–1486
  5. Ries LAG, Kosary CL, Hankey BF, et al.  SEER Cancer Statistics Review, 1973–1996 (NIH publication no. 99–2789). Bethesda, MD: National Cancer Institute; 1996;
  6. Schell SR, Montague ED, Spanos WJ, et al.  Bilateral breast cancer in patients with initial stage I and II disease. Cancer. 1982;50:1191–1194
  7. Rosen PP, Groshen S, Kinne DW, et al.  Contralateral breast carcinoma (An assessment of risk and prognosis in stage I (T1N0M0) and stage II (T1N1M0) patients with 20-year follow-up). Surgery. 1989;106:904–910
  8. Iglehart JD. Prophylactic mastectomy. In:  Harris JR editors. Diseases of the Breast. ed 2. Philadelphia, PA: Lippincott Williams & Wilkins; 2000;p. 255–264
  9. Morrow M, Harris JR. Local management of invasive breast cancer. In:  Harris JR editors. Diseases of the Breast. ed 2. Philadelphia, PA: Lippincott Williams & Wilkins; 2000;p. 515–560
  10. Thomas DB, Gao DL, Ray RM, et al.  Randomized trial of breast self-examination in Shanghai (Final results). J Natl Cancer Inst. 2002;94:1445–1457
  11. Hartmann LC, Schaid DJ, Woods JE, et al.  Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med. 1999;340:77–84
  12. Rebbeck TR, Lynch HT, Neuhausen SL, et al.  Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med. 2002;346:1616–1622
  13. Burke W, Daly M, Garber J, et al.  Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium. JAMA. 1997;277:997–1003
  14. Morris EA. Breast cancer imaging with MRI. Radiol Clin North Am. 2002;40:443–466
  15. Schnall MD. Application of magnetic resonance imaging to early detection of breast cancer. Breast Cancer Res. 2001;3:17–21
  16. Rosselli Del Turco M, Palli D, Cariddi A, et al.  Intensive diagnostic follow-up after treatment of primary breast cancer. A randomized trial. National Research Council Project on Breast Cancer follow-up. JAMA. 1994;271:1593–1597
  17. The GIVIO Investigators . Impact of follow-up testing on survival and health-related quality of life in breast cancer patients. A multicenter randomized controlled trial. JAMA. 1994;271:1587–1592
  18. Smith TJ, Davidson NE, Schapira DV, et al.  American Society of Clinical Oncology 1998 update of recommended breast cancer surveillance guidelines. J Clin Oncol. 1999;17:1080–1082
  19. American Society of Clinical Oncology . Recommended Breast Cancer Surveillance. 2003; www.asco.org; accessed Sept 30, 2003
  20. Fertig DL, Hayes DF. Psychological responses to tumor markers. In:  Holland JC editors. Psycho-oncology. New York, NY: Oxford University Press; 1998;p. 147–160
  21. Partridge AH, Wang PS, Winer EP, et al.  Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol. 2003;21:602–606
  22. Earle CC, Burstein HJ, Winer EP, et al.  Quality of non-breast cancer health maintenance among elderly breast cancer survivors. J Clin Oncol. 2003;21:1447–1451
  23. Harcourt DM, Rumsey NJ, Ambler NR, et al.  The psychological effect of mastectomy with or without breast reconstruction (A prospective, multicenter study). Plast Reconstr Surg. 2003;111:1060–1068
  24. Johnson CH, van Heerden JA, Donohue JH, et al.  Oncological aspects of immediate breast reconstruction following mastectomy for malignancy. Arch Surg. 1989;124:819–823
  25. Slavin SA, Love SM, Goldwyn RM. Recurrent breast cancer following immediate reconstruction with myocutaneous flaps. Plast Reconstr Surg. 1994;93:1191–1204
  26. Hasen KV, Few JW, Fine NA. Plastic surgery (A component in the comprehensive care of cancer patients). Oncology (Huntingt). 2002;16:1685–1698
  27. Schuster RH, Kuske RR, Young VL, et al.  Breast reconstruction in women treated with radiation therapy for breast cancer (Cosmesis, complications, and tumor control). Plast Reconstr Surg. 1992;90:445–452
  28. Evans GR, Schusterman MA, Kroll SS, et al.  Reconstruction and the radiated breast (Is there a role for implants?). Plast Reconstr Surg. 1995;96:1111–1115
  29. Tran NV, Evans GR, Kroll SS, et al.  Postoperative adjuvant irradiation (Effects on tranverse rectus abdominis muscle flap breast reconstruction). Plast Reconstr Surg. 2000;106:313–317
  30. Spear SL, Onyewu C. Staged breast reconstruction with saline-filled implants in the irradiated breast (recent trends and therapeutic implications). Plast Reconstr Surg. 2000;105:930–942
  31. Warmuth MA, Bowen G, Prosnitz LR, et al.  Complications of axillary lymph node dissection for carcinoma of the breast (a report based on a patient survey). Cancer. 1998;83:1362–1368
  32. Haid A, Kuehn T, Konstantiniuk P, et al.  Shoulder-arm morbidity following axillary dissection and sentinel node only biopsy for breast cancer. Eur J Surg Oncol. 2002;28:705–710
  33. Kelemen PR. Comprehensive review of sentinel lymphadenectomy in breast cancer. Clin Breast Cancer. 2000;1:111–125
  34. Meric F, Buchholz TA, Mirza NQ, et al.  Long-term complications associated with breast-conservation surgery and radiotherapy. Ann Surg Oncol. 2002;9:543–549
  35. Petrek JA, Senie RT, Peters M, et al.  Lymphedema in a cohort of breast carcinoma survivors 20 years after diagnosis. Cancer. 2001;92:1368–1377
  36. Kwan W, Jackson J, Weir LM, et al.  Chronic arm morbidity after curative breast cancer treatment (Prevalence and impact on quality of life). J Clin Oncol. 2002;20:4242–4248
  37. Herd-Smith A, Russo A, Muraca MG, et al.  Prognostic factors for lymphedema after primary treatment of breast carcinoma. Cancer. 2001;92:1783–1787
  38. Beenken SW, Bland KI. Long-term complications of breast-conservation therapy (Can the incidence be reduced?). Ann Surg Oncol. 2002;9:524–525
  39. Paskett ED, Stark N. Lymphedema (Knowledge, treatment, and impact among breast cancer survivors). Breast J. 2000;6:373–378
  40. Harris SR, Hugi MR, Olivotto IA, et al.  Clinical practice guidelines for the care and treatment of breast cancer (11. Lymphedema). Can Med Assoc J. 2001;164:191–199
  41. Beaulac SM, McNair LA, Scott TE, et al.  Lymphedema and quality of life in survivors of early-stage breast cancer. Arch Surg. 2002;137:1253–1257
  42. Rockson SG. Precipitating factors in lymphedema (Myths and realities). Cancer. 1998;83:2814–2816
  43. Ovarian ablation in early breast cancer . Overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative Group. Lancet. 1996;348:1189–1196
  44. Tamoxifen for early breast cancer . An overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative Group. Lancet. 1998;351:1451–1467
  45. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer (First results of the ATAC randomised trial). Lancet. 2002;359:2131–2139
  46. Lipton A, Harvey HA, Hamilton RW. Venous thrombosis as a side effect of tamoxifen treatment. Cancer Treat Rep. 1984;68:887–889
  47. Love RR. Tamoxifen therapy in early breast cancer (Biology, efficacy and side effects). J Clin Oncol. 1989;7:803–815
  48. Van Leeuwen FE, Benraadt J, Coebergh JWW. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet. 1994;343:448–452
  49. Fisher B, Dignam J, Bryant J, et al.  Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst. 1996;88:1529–1542
  50. Fisher B, Costantino JP, Wickerham DL, et al.  Tamoxifen for prevention of breast cancer (Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study). J Natl Cancer Inst. 1998;90:1371–1388
  51. Paganini-Hill A, Clark LJ. Eye problems in breast cancer patients treated with tamoxifen. Breast Cancer Res Treat. 2000;60:167–172
  52. Wysowski DK, Honig SF, Beitz J. Uterine sarcoma associated with tamoxifen use. N Engl J Med. 2002;346:1832–1833
  53. Wickerham DL, Fisher B, Wolmark N, et al.  Association of tamoxifen and uterine sarcoma. J Clin Oncol. 2002;20:2758–2760
  54. Davidson N, O’Neill A, Vukov A, et al.  Effect of chemohormonal therapy in premenopausal node (+) receptor (+) breast cancer (An Eastern Cooperative Oncology Group Phase III Intergroup Trial (E5188, INT-0101)). Proc Am Soc Clin Oncol. 1999;18:67a; (abstr)
  55. Davidson NE. Ovarian ablation as adjuvant therapy for breast cancer. J Natl Cancer Inst Monogr. 2001;30:67–71
  56. Emens LA, Davidson NE. Adjuvant hormonal therapy for premenopausal women with breast cancer. Clin Cancer Res. 2003;9(suppl):486S–494S
  57. Jonat W. Role of LHRH agonists in premenopausal women with oestrogen receptor-positive breast cancer (The ZEBRA experience). Eur J Cancer. 2002;38(suppl 6):S39–S40
  58. Winer EP, Hudis C, Burstein HJ, et al.  American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer (status report 2002). J Clin Oncol. 2002;20:3317–3327
  59. Eastell R, Adams J. Results of the arimidex, tamoxifen, alone or in combination trial (effects on bone mineral density and bone turnover). Ann Oncol. 2002;13:32; (abstr 113)
  60. Ganz PA, Coscarelli A, Fred C, et al.  Breast cancer survivors (Psychosocial concerns and quality of life). Breast Cancer Res Treat. 1996;38:183–199
  61. Ganz PA, Rowland JH, Desmond K, et al.  Life after breast cancer (Understanding women’s health-related quality of life and sexual functioning). J Clin Oncol. 1998;16:501–514
  62. Meyerowitz BE, Desmond KA, Rowland JH, et al.  Sexuality following breast cancer. J Sex Marital Ther. 1999;25:237–250
  63. Ganz PA. Menopause and breast cancer (Symptoms, late effects, and their management). Semin Oncol. 2001;28:274–283
  64. Barton DL, Loprinzi C, Gostout B. Current management of menopausal symptoms in cancer patients. Oncology (Huntingt). 2002;16:67–72
  65. Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med. 1998;339:1609–1618
  66. Partridge AH, Burstein HJ, Winer EP. Side effects of chemotherapy and combined chemohormonal therapy in women with early-stage breast cancer. J Natl Cancer Inst Monogr. 2001;30:135–142
  67. Gelber S, Coates AS, Goldhirsch A, et al.  Effect of pregnancy on overall survival after the diagnosis of early- stage breast cancer. J Clin Oncol. 2001;19:1671–1675
  68. Dow KH, Harris JR, Roy C. Pregnancy after breast-conserving surgery and radiation therapy for breast cancer. J Natl Cancer Inst Monogr. 1994;16:131–137
  69. Kroman N, Jensen MB, Melbye M, et al.  Should women be advised against pregnancy after breast-cancer treatment?. Lancet. 1997;350:319–322
  70. Sankila R, Heinavaara S, Hakulinen T. Survival of breast cancer patients after subsequent term pregnancy (“Healthy mother effect.”). Am J Obstet Gynecol. 1994;170:818–823
  71. Velentgas P, Daling JR, Malone KE, et al.  Pregnancy after breast carcinoma (Outcomes and influence on mortality). Cancer. 1999;85:2424–2432
  72. von Schoultz E, Johansson H, Wilking N, et al.  Influence of prior and subsequent pregnancy on breast cancer prognosis. J Clin Oncol. 1995;13:430–434
  73. Surbone A, Petrek JA. Childbearing issues in breast carcinoma survivors. Cancer. 1997;79:1271–1278
  74. Duckitt K, Templeton AA. Cancer in women with infertility. Curr Opin Obstet Gynecol. 1998;10:199–203
  75. Venn A, Watson L, Bruinsma F, et al.  Risk of cancer after use of fertility drugs with in-vitro fertilisation. Lancet. 1999;354:1586–1590
  76. Danforth DN. How subsequent pregnancy affects outcome in women with a prior breast cancer. Oncology (Huntingt). 1991;5:23–30
  77. Byrne J, Fears TR, Gail MH, et al.  Early menopause in long-term survivors of cancer during adolescence. Am J Obstet Gynecol. 1992;166:788–793
  78. Tewari K, Bonebrake RG, Asrat T. Ambiguous genitalia in infant exposed to tamoxifen in utero. Lancet. 1997;350:183
  79. Cullins SL, Pridjian G, Sutherland CM. Goldenhar’s syndrome associated with tamoxifen given to the mother during gestation. JAMA. 1994;271:1905–1906
  80. Dow KH. Having children after breast cancer. Cancer Pract. 1994;2:407–413
  81. Higgins S, Haffty BG. Pregnancy and lactation after breast-conserving therapy for early stage breast cancer. Cancer. 1994;73:2175–2180
  82. Tralins AH. Lactation after conservative breast surgery combined with radiation therapy. Am J Clin Oncol. 1995;18:40–43
  83. Vassilopoulou-Sellin R, Asmar L, Hortobagyi GN, et al.  Estrogen replacement therapy after localized breast cancer (Clinical outcome of 319 women followed prospectively). J Clin Oncol. 1999;17:1482–1487
  84. Santen R, Pritchard K, Burger H. The consensus conference on treatment of estrogen deficiency symptoms in women surviving breast cancer. Obstet Gynecol Surv. 1998;53(suppl):S1–S83
  85. Rossouw JE, Anderson GL, Prentice RL, et al.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women (Principal results From the Women’s Health Initiative randomized controlled trial). JAMA. 2002;288:321–333
  86. Powles TJ, Hickish T, Casey S, et al.  Hormone replacement after breast cancer. Lancet. 1993;342:60–61
  87. Ganz PA, Desmond KA, Leedham B, et al.  Quality of life in long-term, disease-free survivors of breast cancer (A follow-up study). J Natl Cancer Inst. 2002;94:39–49
  88. Ganz PA. Quality of life across the continuum of breast cancer care. Breast J. 2000;6:324–330

PII: S0093-7754(03)00476-7

doi: 10.1053/j.seminoncol.2003.08.026

Seminars in Oncology
Volume 30, Issue 6 , Pages 817-825 , December 2003

Article Tools

* Image Usage & Resolution